What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?

Thuny F, Bonaca MP, Cautela J

Open source

DOI
10.1016/j.jaccao.2022.06.008
Published
2022 Dec
Container
JACC. CardioOncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jaccao.2022.06.008,
  title = {What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?},
  author = {Thuny F and Bonaca MP and Cautela J},
  year = {2022},
  journal = {JACC. CardioOncology},
  doi = {10.1016/j.jaccao.2022.06.008},
  url = {https://doi.org/10.1016/j.jaccao.2022.06.008}
}

RIS

TY  - JOUR
TI  - What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?
AU  - Thuny F
AU  - Bonaca MP
AU  - Cautela J
PY  - 2022
JO  - JACC. CardioOncology
DO  - 10.1016/j.jaccao.2022.06.008
UR  - https://doi.org/10.1016/j.jaccao.2022.06.008
ER  - 

APA

F, T., MP, B., & J, C. (2022). What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?. JACC. CardioOncology. https://doi.org/10.1016/j.jaccao.2022.06.008

Source records